Single answer

Is Alumis Inc Common Stock (ALMS) a buy or sell?

4starter turns market data into one clear verdict you can act on.

Sell
$28.90
-0.489 (-1.66%)
Quote updated: 2026-02-26 19:24 UTC
Trend today
-1.66%
Down today
Volume vs avg
86.54%
0.13x under average
Target gap
29.75%
above current price
Signal updated
2026-02-26 18:21 UTC
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Add to watchlist

Create a free account to save tickers and track your signals.

Log in to turn on watchlist alerts.

Decision snapshot

Everything you need to act fast, in one glance.

4starter signal
Sell
20%
Score
Confidence score
Higher scores mean stronger signal alignment.

Powered by momentum, volatility, and trend inputs.

Analyst target gap
29.75%
$8.60 above current price

Consensus target $37.50.

Volume vs average
86.54%
under average

398,018 vs 3M average (0.13x normal).

What is the conclusion?

Right now our advanced algorithms say:

NO

$1 invested is now $1.53 or 52.58%

(In 7 weeks 1 day 3 hours 48 minutes and 22 seconds .)

Do analysts agree?

We compare consensus targets with today's price.

NO

Consensus target for Alumis Inc Common Stock is $37.50, which is $8.60 (29.75%) above the current price today's price.

Low target: $32.00 | High target: $50.00

Latest analyst updates

Recent rating and price target changes for this stock.

2026-01-21 | Chardan Capital | Target 37.00
2026-01-21 | Loop Capital Markets | Target 37.00
2026-01-09 | H.C. Wainwright | Target 40.00
2026-01-07 | Morgan Stanley | Target 33.00
2026-01-07 | Guggenheim | Target 32.00

Company snapshot

A quick overview of the business and its public profile.

Alumis Inc a clinical stage biopharmaceutical company focuses on the development and commercialization of medicines for autoimmune disorders It develops ESK001 an allosteric tyrosine kinase 2 TYK2 inhibitor for the treatment of plaque psoriasis systemic lupus erythematosus and noninfectious uveitis and A005 a central nervous systempenetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases The company was formerly known as Esker Therapeutics Inc and changed its name to Alumis Inc in January 2022 The company was incorporated in 2021 and is headquartered in South San Francisco California

Website: https://www.alumis.com

Rates and inflation backdrop

US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.

Inflation sensitivity

Debt ratio: 0.08. Cash flow to debt ratio: -9.85. Net profit margin: -1,108.24%. Inflation risk score: medium (0.70/1).

Dividend history check

We cannot find any recorded dividends paid in our systems.

Trading liquidity

Yes, the average daily trading liquidity for Alumis Inc Common Stock is $34.9M. You should therefore be able to get in and out of your positions relatively fast.

10-year return check

We cannot find data for Alumis Inc Common Stock 10 years ago, but if you had invested on 2024-06-28 when the price was $13.30, you would have made a profit of $16.09 per share or 120.98%.

Why this answer

We combine price momentum, volatility, and trend signals to simplify the decision to one word.

1

Signal engine scans price, trend, and momentum indicators.

2

Targets and sentiment are checked against the live quote.

3

We keep the output simple: buy, sell, or hold.

Analyst consensus

How Wall Street targets compare to today's price.

$37.50
$8.60 (29.75%) above the current price
Range: $32.00 - $50.00

FAQ

Today's 4starter signal is Sell. That means the current data favors caution over upside.

Quotes and targets refresh throughout the trading day, with the latest timestamp shown on the page.

It blends momentum, trend, and volatility indicators into a single decision-oriented verdict.